← back to search

Sally Ellis

New South Wales Department of Health ·
Area of research
Public Health, Environmental and Occupational Health · History and Philosophy of Science
Research interest
Research focused on Miltefosine and Visceral leishmaniasis, with related work in Antibiotic resistance, Sodium stibogluconate, Colistin. Notable publications include 'Sodium Stibogluconate (SSG) & Paromomycin Combination Compared to SSG for Visceral Leishmaniasis in East Africa: A Randomised Controlled Trial', 'Patterns of antibiotic use, pathogens, and prediction of mortality in hospitalized neonates and young infants with sepsis: A global neonatal sepsis observational cohort study...', and 'Systematic review and meta-analysis of in vitro efficacy of antibiotic combination therapy against carbapenem-resistant Gram-negative bacilli'.
h-index
citations
799
works
8
NIH funding
primary concept
email

Recent publications

The burden of bacterial antimicrobial resistance in the WHO Eastern Mediterranean Region 1990–2021: a cross-country systematic analysis with forecasts to 2050
The Lancet Public Health 2025cited by 15position: middledoi
Patterns of antibiotic use, pathogens, and prediction of mortality in hospitalized neonates and young infants with sepsis: A global neonatal sepsis observational cohort study (NeoOBS)
PLoS Medicine 2023cited by 162position: middledoi
Antibiotics needed to treat multidrug-resistant infections in neonates
Bulletin of the World Health Organization 2022cited by 60position: middledoi
Systematic review and meta-analysis of in vitro efficacy of antibiotic combination therapy against carbapenem-resistant Gram-negative bacilli
International Journal of Antimicrobial Agents 2021cited by 104position: middledoi
A randomized trial of AmBisome monotherapy and AmBisome and miltefosine combination to treat visceral leishmaniasis in HIV co-infected patients in Ethiopia
PLoS neglected tropical diseases 2019cited by 83position: middledoi
Efficacy and Safety of AmBisome in Combination with Sodium Stibogluconate or Miltefosine and Miltefosine Monotherapy for African Visceral Leishmaniasis: Phase II Randomized Trial
PLoS neglected tropical diseases 2016cited by 104position: middledoi
Safety and Efficacy of Single Dose versus Multiple Doses of AmBisome® for Treatment of Visceral Leishmaniasis in Eastern Africa: A Randomised Trial
PLoS neglected tropical diseases 2014cited by 100position: middledoi
Sodium Stibogluconate (SSG) & Paromomycin Combination Compared to SSG for Visceral Leishmaniasis in East Africa: A Randomised Controlled Trial
PLoS neglected tropical diseases 2012cited by 171position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Asrat Hailu · The Ohio State University Wexner Medical Center3 papers (2014–2019) · 3 papers (2014–2019) · 3 papers (2014–2019)Tansy Edwards · London School of Hygiene & Tropical Medicine3 papers (2014–2019) · 3 papers (2014–2022) · 3 papers (2014–2019)Ahmed Musa · University of Khartoum2 papers (2014–2016) · 2 papers (2014–2016)Eltahir Awad Gasim Khalil · London School of Hygiene & Tropical Medicine2 papers (2014–2016)Neâl Alexander · London School of Hygiene & Tropical Medicine2 papers (2016–2019)Nathalie Strub‐Wourgaft · Université Paris-Panthéon-Assas2 papers (2016–2019)Thomas P. C. Dorlo · Utrecht University2 papers (2014–2016) · 2 papers (2016–2019)Sithembiso Velaphi · Korle Bu Teaching Hospital1 papers (2022–2022)Thomas P. Lodise · Albany Medical Center Hospital1 papers (2021–2021) · 1 papers (2019–2019)Maurizio Sanguinetti · Corvid Technologies (United States)1 papers (2021–2021) · 1 papers (2019–2019)Gary J. Noel · Gamal Abdel Nasser University of Conakry1 papers (2022–2022) · 1 papers (2021–2021)